نتایج جستجو برای: hbc antibody

تعداد نتایج: 167575  

2015
Amitis Ramezani Mohammad Reza Aghasadeghi Farrokhlagha Ahmadi Effat Razeghi Ali Eslamifar Mohammad Banifazl Masoomeh Sofian Golnaz Bahramali Soheila Hekmat Arezoo Aghakhani

BACKGROUND Occult Hepatitis B virus (HBV) infection (OBI) is defined as the presence of HBV-DNA in the liver or serum with undetectable hepatitis B surface antigen (HBsAg). Hemodialysis (HD) patients are at risk of acquiring parenterally transmitted infections. OBJECTIVES The aim of this study was to assess the prevalence of OBI in HD patients. PATIENTS AND METHODS A hundred HBsAg negative ...

Journal: :Journal of clinical pathology 1989
S Kakumu M Arao K Yoshioka Y Tsutsumi M Inoue

To evaluate the role of the expression of hepatitis B core antigen (HBcAg) in liver cell damage the immunoperoxidase staining pattern of cryostat liver biopsy specimens from 16 chronic carriers of hepatitis B surface antigen (HBsAg) was investigated using three different kinds of anti-HBc antibodies. Polyclonal antibody prepared from recombinant HBcAg seemed to be more sensitive in detecting HB...

Journal: :Postgraduate medical journal 1982
R G Chadwick A J Hall I Davidson F G Bull R Wright

Six hundred and thirty-two blood samples from 879 consecutive admissions to one resettlement camp for Indochinese refugees in Great Britain were screened for markers of hepatitis B (HB) virus infection. The overall prevalence of HB surface antigen (HBsAg) was 15%, being 16% in those aged 40 years or less, and falling to 8% in those older than 40 (P less than 0.05). No significant difference in ...

Background and Aims: Occult hepatitis B virus infection (OBI) is known as an important source of hepatitis B virus (HBV) infection. It is categorized as Hepatitis B surface antigen (HBsAg) not being present and low DNA viral load in serum. In this study, an attempt was made to investigate the outbreak of anti-HBc and OBI among the HBsAg-negative donors in Golestan province. Materials and Metho...

2013
Mariko Kyutoku Hironori Nakagami Hiroshi Koriyama Hideki Tomioka Futoshi Nakagami Munehisa Shimamura Hitomi Kurinami Pang Zhengda Dong Hyun Jo Jeong Hun Kim Nobuyuki Takakura Ryuichi Morishita

We developed DNA vaccine for vascular endothelial growth factor (VEGF), which may provide the therapeutic option instead of anti-VEGF antibody, bevacizumab. Plasmid containing VEGF mini-gene was constructed in the insertion of B-cell epitope of Hepatitis B core protein [HBc-VEGF], which was an epitope carrier. High titer of anti-VEGF antibody was observed in BALB/c mice which were intramuscular...

2017
Min-ran Li Huan-wei Zheng Jian-hua Lu Shun-mao Ma Li-hong Ye Zhi-quan Liu Hai-cong Zhang Yun-yan Liu Ying Lv Yan Huang Er-hei Dai Dian-xing Sun

BACKGROUND Previous studies have revealed that hepatitis B core antibody (anti-HBc) levels vary throughout the different phases of treatment-naïve chronic hepatitis B (CHB) patients and can be used as a predictor of treatment response in both interferon-α and nucleoside analogue therapies. However, few data have been published regarding the relationship between quantitative anti-HBc (qAnti-HBc)...

2014
Wei Jia Liu-Wei Song Yu-Qing Fang Xiao-Feng Wu Dan-Yang Liu Chun Xu Xiao-Mei Wang Wen Wang Dong-Xia Lv Jun Li Yong-Qiong Deng Yan Wang Na Huo Min Yu Hong-Li Xi Dan Liu Yi-Xing Zhou Gui-Qiang Wang Ning-Shao Xia Ming-Xiang Zhang Maissa El Said El Raziky.

Previous studies have revealed antibody to hepatitis B core antigen (anti-HBc) levels as a predictor of treatment response in hepatitis B early antigen (HBeAg)-positive chronic hepatitis B (CHB) patients in both interferon and nucleos(t)ide analog therapy cohorts. However, there is no information about anti-HBc levels in the natural history of CHB. This study aimed to define anti-HBc levels of ...

Journal: :Journal of the Egyptian National Cancer Institute 2015
Tamer A Elbedewy Hossam Eldin A Elashtokhy Enaam S Rabee Gamal E Kheder

BACKGROUND Occult hepatitis B infection (OBI) is characterized by negative hepatitis B surface antigen (HBsAg) and detectable hepatitis B virus (HBV)-DNA in the liver and/or serum, with or without hepatitis B core antibody (anti-HBc). Anti-HBc is the most sensitive marker of previous HBV. HBV reactivation in patients under immunosuppressive treatment is life-threatening, occurring in both overt...

Journal: :Journal of clinical microbiology 1991
E F Robertson J A Weare R Randell P V Holland G Madsen R H Decker

Addition of reducing agents to competitive assays for antibody to hepatitis B core antigen (anti-HBc) eliminates apparent false reactivity of specimens obtained from individuals with no prior history of hepatitis B virus (HBV) infection and without other serological markers of HBV infection. We have purified and characterized a reduction-sensitive factor (RSF) isolated from the plasma of severa...

Journal: :Journal of clinical pathology 1991
C M Chu S M Lin Y F Liaw

The distribution and quantitative expression of HBcAg in relation to serum HBeAg and liver histology before and after a trial of interferon in 50 patients with chronic type B hepatitis were evaluated using polyclonal and monoclonal antibodies. In general, both antisera showed a similar pattern in terms of the distribution of HBcAg, with predominant localisation of HBcAg in the cytoplasm in HBeA...

نمودار تعداد نتایج جستجو در هر سال

با کلیک روی نمودار نتایج را به سال انتشار فیلتر کنید